OBIGEN and A Phase I Clinical Trial Physician Present New 760 kDa Taiwan Botulinum Toxin at AMWC Japan 2024

OBI-858 Approved by INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA (MyIPO), No. MY-205101-A

OBI-858 Approved by TAIPEI GRAND MOSQUE FOUNDATION For Halal Certificate No. TGM.N13-240702-250831-01B55-1

OBI-858 Approved by Indonesia DIRECTORATE GENERAL OF INTELLECTUAL PROPERTY, No. HKI-3-KI.05.01.08-DP-P00202109681

TFDA CLEARS OBI-858’S IND APPLICATION FOR PHASE II HUMAN CLINICAL TRIAL

Filing of Phase II Human Clinical Trial Application for OBI-858 to Taiwan Food and Drug Administration (TFDA)

OBI-858 Approved by Saudi Authority for Intellectual Property (SAIP), No.521430958

Institutional Director of OBI Pharma Changes Its Representative

OBIGEN and OBI Pharma Sign Exclusive License Agreement for the worldwide therapeutic rights of OBI-858

鼎晉生技獲核定為 ⸢ 生技醫藥公司 ⸥ 資格，投資人租稅優惠解析